Abstracts - Orals, Featured Poster Presentations, and Posters
OR29-Adrenal Tumors & Pheochromocytoma
Presentation Start Time: 11:45 AM
Room 134 (Moscone Center)
Purpose: Even after microscopically complete (R0) resection recurrence of adrenocortical carcinoma (ACC) is frequent. Here we aim at identification of histological parameters with potential prognostic value. Patients and Methods: 318 patients with European Network for the Study of Adrenal Tumours (ENSAT) stage I-III ACC after R0 resection were identified in the German ACC registry and tumour histology reviewed. Histological markers were correlated with recurrence free and overall survival. As an independent validation cohort, we analyzed 250 patients from six European centers. Results: Within the German cohort, univariate analysis identified age at diagnosis, tumor size and lymph node positivity (and correspondingly ENSAT stage) as markers with predictive value for recurrence free survival (RFS). Ki67 index provided the single best prognostic value for recurrence free survival (HR 1.042 per % increase for the German cohort and HR 1.024 for the validation cohort; p<0.001) which was superior to markers evaluated for calculation of the Weiss score. Following multivariate analysis including age, tumor size and adjuvant mitotane treatment Ki67 index remained informative. Similar results were obtainable for overall survival (HR 1.051 per % increase for the German cohort and HR 1.023 for the validation cohort; p<0.001). Conclusion: In conclusion, Ki67 was identified as the single most important prognostic marker for disease recurrence in ACC patients following R0 resection. Our findings will help to guide decisions on adjuvant therapy for this rare disease in the future.
Disclosure: RAF: Clinical Researcher, Novartis Pharmaceuticals, Speaker, Novartis Pharmaceuticals. MT: Ad Hoc Consultant, HRA Pharma. Nothing to Disclose: FB, JO, WS, MK, MQ, UDL, TD, CLR, HW, NR, MR, RL, EB, JYB, HH, RD, PL, BA, HHM, MF
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm